Denali Therapeutics Inc.
Denali Therapeutics Inc. (DNLI): 10 pipeline candidates · 2 upcoming catalysts · ~22 mo cash runway · 9 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
22.2 months
D/E 0.37 · 18% dilution
Lead: Approved
10 candidates
2 upcoming, next in ~348d
0 buys · 2 sells (180d)
A transparent, data-derived signal for Denali Therapeutics Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$3.7B
Cash
$390.7M
Quarterly Burn
$131.2M
Runway
22.2 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (10 candidates)
Upcoming Catalysts (2)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
265
Total value held
$2.35B
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 13,034,434 | $250.3M |
| vanguard capital management llc | 12,295,914 | $236.1M |
| state street corp | 6,272,001 | $120.4M |
| vanguard portfolio management llc | 6,120,160 | $117.5M |
| fmr llc | 4,575,374 | $87.8M |
| crestline management, l.p. | 4,421,464 | $84.9M |
| goldman sachs group inc | 4,407,255 | $84.6M |
| baker bros. advisors lp | 3,731,695 | $71.6M |
| geode capital management, llc | 3,727,114 | $71.6M |
| holocene advisors, lp | 3,195,429 | $61.4M |
Showing top 10 of 265 institutional holders of Denali Therapeutics Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Denali Therapeutics Inc.'s pipeline?
Denali Therapeutics Inc. (DNLI) has 10 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Denali Therapeutics Inc.'s lead drug candidate?
Denali Therapeutics Inc.'s most advanced tracked candidate is avlayah (Approved) for 1 INDICATIONS AND USAGE AVLAYAH is indicated for the treatment of neurologic manifestations of Hunter syndrome (Mucopolysaccharidosis type II, MPS II) when initiated in presymptomatic or symptomatic pediatric patients weighing at least 5 kg prior to advanced neurologic impairment. This indication is approved under accelerated approval based on the reduction of cerebrospinal fluid heparan sulfate [see Clinical Studies (14) ] . Continued approval for this indication may be contingent upon verifica.
What is Denali Therapeutics Inc.'s next catalyst?
Denali Therapeutics Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: An Open-Label Extension to Investigate the Long-Term Safety, Tolerability, and Efficacy of DNL310 in" — expected June 1, 2027.
What is Denali Therapeutics Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Denali Therapeutics Inc. has approximately 22.2 months of cash runway.
What is Denali Therapeutics Inc.'s market capitalization?
Denali Therapeutics Inc.'s market capitalization is approximately $3.7B.
Get the full picture on Denali Therapeutics Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.